No Data
Kemei Diagnostics (688468.SH): Shanghai Peixi and its concerted actors have collectively reduced their shareholding by 3%.
Gelonghui, December 19th丨Kemei Diagnosis (688468.SH) announced that on October 14, 2024, the company disclosed the "Announcement of Shareholding Reduction Plan by Shareholders Holding More Than 5% of Kemei Diagnosis Technology Co., Ltd." Shanghai Peixi and its concerted parties HJCAPITAL plan to reduce their shareholding through centralized bidding and block trading, and the total reduction is expected not to exceed 12,033,240 shares, accounting for no more than 3.00% of the company’s total equity. On December 18, 2024, the company received a notice from the above shareholders regarding the implementation results of the share reduction plan.
Co-Rays Diagnostics (688468.SH): Hengqin Junlian Zhi Kang and its concerted parties have cumulatively reduced their shareholding by 1.99%.
Gelonghui, November 6th - Kemei Diagnostics (688468.SH) announced that on November 5, 2024, the company received a brief equity changes report from the company's shareholder Hengqin Junlian ZhiKang and its concerted action person LOYALCLASS. During the period from August 15, 2024 to November 5, 2024. Hengqin Junlian ZhiKang and its concerted action person LOYALCLASS collectively reduced their shareholding in the company by 7,975,214 shares, accounting for 1.99% of the total share capital of the company. After this equity change, Hengqin Junlian ZhiKang and its
Komei Diagnostic Technology Co., Ltd. Third Quarter Report 2024
Chemclin Diagnostics Co., Ltd.'s (SHSE:688468) Share Price Boosted 36% But Its Business Prospects Need A Lift Too
Komei Diagnostic Technology Co., Ltd. 2024 Semi-Annual Report
Summary of the 2024 semi-annual report of Komei Diagnostic Technology Co., Ltd.
Chemclin Diagnostics Co., Ltd.'s (SHSE:688468) Business And Shares Still Trailing The Market
